The Swinging Pendulum in Treatment for Hypothyroidism: From (and Toward?) Combination Therapy
Open accessThe DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
Abstract
Thyroid hormone replacement for hypothyroidism can be achieved via several approaches utilizing different preparations of thyroid hormones, T3 and/or T4. ‘Combination therapy’ involves administration of both T3 and T4, and was technically the first treatment for hypothyroidism. It was lauded as a cure for the morbidity and mortality associated with myxedema, the most severe presentation of overt hypothyroidism. In the late 19th and the early 20th centuries, combination therapy per se could consist of thyroid gland transplant, or more commonly, consumption of desiccated animal thyroid, thyroid extract or thyroglobulin. Combination therapy remained the mainstay of therapy for decades despite development of synthetic formulations of T4 and T3, because it was efficacious and cost effective. However, concerns emerged about the consistency and potency of desiccated thyroid hormone after cases were reported detailing either continued hypothyroidism or iatrogenic thyrotoxicosis. Development of the TSH radioimmunoassay and discovery of conversion of T4-to-T3 in humans led to a major transition in clinical practices away from combination therapy, to adoption of levothyroxine ‘monotherapy’ as the standard of care. Levothyroxine monotherapy has a favorable safety profile and can effectively normalize the serum TSH, the most sensitive marker of hypothyroidism. Whether levothyroxine monotherapy restores thyroid hormone signaling within all tissues remains controversial. Evidence of persistent signs and symptoms of hypothyroidism during levothyroxine monotherapy at doses that normalize serum TSH is mounting. Hence, in the last decade there has been acknowledgement by all thyroid professional societies that there may be a role for the use of combination therapy; this represents a significant shift in the clinical practice guidelines. Further bolstering this trend are the recent findings that the Thr92AlaD2 polymorphism may reduce thyroid hormone signaling, resulting in localized and systemic hypothyroidism. This strengthens the hypothesis that treatment options could be personalized, taking into consideration genotypes and comorbidities. The development of long-acting formulations of liothyronine and continued advancements in development of thyroid regenerative therapy, may propel the field closer to adoption of a physiologic thyroid hormone replacement regimen with combination therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Colorado Thyroid Disease Prevalence Study
Canaris, G. J., Manowitz, N. R., Mayor, G., & Ridgway, E. C. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.4.526 · Cited by 2,824
Jonklaas, J., Bianco, A. C., Bauer, A. J., Burman, K. D., Cappola, A. R., Celi, F. S., Cooper, D. S., Kim, B. W., Peeters, R. P., Rosenthal, M. S., et al. (2014) · Thyroid® · doi:10.1089/thy.2014.0028 · Cited by 1,928
Self-citationGarber, J. R., Cobin, R. H., Gharib, H., Hennessey, J. V., Klein, I., Mechanick, J. I., Pessah-Pollack, R., Singer, P. A., & Woeber, K. A. (2012) · Endocrine Practice · doi:10.4158/ep12280.gl · Cited by 1,567 · cited 6×
“These recommendations were similarly upheld in the ATA/AACE guidelines in 2012 (131).”
BackgroundMethodResultInfluentialGarber, J. R., Cobin, R. H., Gharib, H., Hennessey, J. V., Klein, I., Mechanick, J. I., Pessah-Pollack, R., Singer, P. A., & Woeber for the American Association, K. A. (2012) · Thyroid · doi:10.1089/thy.2012.0205 · Cited by 1,053
Duntas, L. H. (2002) · Thyroid · doi:10.1089/10507250252949405 · Cited by 725
Baskin, H. J., Cobin, R. H., Duick, D. S., Gharib, H., Guttler, R. B., Kaplan, M. M., Segal, R. L., Garber, J. R., Hamilton Jr, C. R., Handelsman, Y., et al. (2002) · Endocrine Practice · doi:10.4158/1934-2403-8.6.457 · Cited by 673
Saravanan, P., Chau, W. ‐., Roberts, N., Vedhara, K., Greenwood, R., & Dayan, C. M. (2002) · Clinical Endocrinology · doi:10.1046/j.1365-2265.2002.01654.x · Cited by 514 · cited 4×
“However, LT4-treated patients display significant impairment in psychological well-being compared to controls of similar age and sex (14).”
BackgroundInfluentialConversion of Thyroxine (T4) to triiodothyronine (T3) in athyreotic human subjects
Braverman, L. E., Ingbar, S. H., & Sterling, K. (1970) · Journal of Clinical Investigation · doi:10.1172/jci106304 · Cited by 485
Bunevičius, R., Kažanavičius, G., Žalinkevičius, R., & Prange, A. J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199902113400603 · Cited by 482 · cited 2×
“Indeed, many clinical trials show subjective “preference” for combination therapy without positive objective results when utilizing quality of life and/or thyroid-specific questionnaires (19, 21, 128, 129).”
Background2012 ETA Guidelines: The Use of L-T4 + L-T3 in the Treatment of Hypothyroidism
Wiersinga, W. M., Duntas, L., Fadeyev, V., Nygaard, B., & Vanderpump, M. P. J. (2012) · European Thyroid Journal · doi:10.1159/000339444 · Cited by 437
Treatment Guidelines for Patients With Hyperthyroidism and Hypothyroidism
Singer, P. A. (1995) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1995.03520340064038 · Cited by 427 · cited 5×
“These guidelines have been evolving away from a universal approach with LT4 monotherapy (23, 24, 131) and toward an approach that accepts a therapeutic trial of combination therapy for select patients (Table 1) (1, 26, 27).”
BackgroundResultInfluentialGeneration of functional thyroid from embryonic stem cells
Antonica, F., Kasprzyk, D. F., Opitz, R., Iacovino, M., Liao, X.-H., Dumitrescu, A. M., Refetoff, S., Peremans, K., Manto, M., Kyba, M., et al. (2012) · Nature · doi:10.1038/nature11525 · Cited by 359
Panicker, V., Saravanan, P., Vaidya, B., Evans, J., Hattersley, A. T., Frayling, T. M., & Dayan, C. M. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1301 · Cited by 327
Levothyroxine Monotherapy Cannot Guarantee Euthyroidism in All Athyreotic Patients
Gullo, D., Latina, A., Frasca, F., Le Moli, R., Pellegriti, G., & Vigneri, R. (2011) · PLoS ONE · doi:10.1371/journal.pone.0022552 · Cited by 307
Taylor, P. N., Iqbal, A., Minassian, C., Sayers, A., Draman, M. S., Greenwood, R., Hamilton, W., Okosieme, O., Panicker, V., Thomas, S. L., et al. (2014) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.11312 · Cited by 300
Feller, M., Snel, M., Moutzouri, E., Bauer, D. C., de Montmollin, M., Aujesky, D., Ford, I., Gussekloo, J., Kearney, P. M., Mooijaart, S., et al. (2018) · JAMA · doi:10.1001/jama.2018.13770 · Cited by 266 · cited 1×
“Prescribing patterns have changed such that serum TSH level at time of initial treatment has been decreasing (124, 125) yet this may not improve quality of life or thyroid-related symptoms (126).”
BackgroundEscobar-Morreale, H. F., del Rey, F. E., Obregón, M. J., & de Escobar, G. M. (1996) · Endocrinology · doi:10.1210/endo.137.6.8641203 · Cited by 261 · cited 3×
“Only steady delivery of LT4 and LT3 in thyroidectomized rats fully normalizes serum and tissue T3 levels (30), as well as T3-dependent metabolic markers and gene expression profiles in this animal model (29).”
BackgroundAn Online Survey of Hypothyroid Patients Demonstrates Prominent Dissatisfaction
Peterson, S. J., Cappola, A. R., Castro, M. R., Dayan, C. M., Farwell, A. P., Hennessey, J. V., Kopp, P. A., Ross, D. S., Samuels, M. H., Sawka, A. M., et al. (2018) · Thyroid · doi:10.1089/thy.2017.0681 · Cited by 231 · cited 1×
“The efficacy of LT4 monotherapy has come into question as with this approach, 10–15% of patients express dissatisfaction due to residual symptoms of hypothyroidism (12, 13), and specifically cognitive impairment (14, 15).”
BackgroundSelf-citationSurks, M. I., Schadlow, A. R., Stock, J. M., & Oppenheimer, J. H. (1973) · Journal of Clinical Investigation · doi:10.1172/jci107244 · Cited by 223
Triiodothyronine Levels in Athyreotic Individuals During Levothyroxine Therapy
Jonklaas, J. (2008) · JAMA · doi:10.1001/jama.299.7.769 · Cited by 216
Okosieme, O., Gilbert, J., Abraham, P., Boelaert, K., Dayan, C., Gurnell, M., Leese, G., McCabe, C., Perros, P., Smith, V., et al. (2016) · Clinical Endocrinology · doi:10.1111/cen.12824 · Cited by 208
Surks, M. I., Schadlow, A. R., & Oppenheimer, J. H. (1972) · Journal of Clinical Investigation · doi:10.1172/jci107137 · Cited by 188 · cited 2×
“That a single daily dose of oral LT4 resulted in nearly seemingly physiologic, stable blood levels of T4 and T3 throughout the day (107) was understood to be a result of a steady rate of conversion of T4-to-T3 (110, 111).”
BackgroundWerneck de Castro, J. P., Fonseca, T. L., Ueta, C. B., McAninch, E. A., Abdalla, S., Wittmann, G., Lechan, R. M., Gereben, B., & Bianco, A. C. (2015) · Journal of Clinical Investigation · doi:10.1172/jci77588 · Cited by 184 · cited 5×
“Yet, the brain, liver and skeletal muscle tissues of these LT4-treated animals exhibit markers of localized hypothyroidism (29), likely due the inability of LT4 monotherapy to restore tissue levels of T3 (30).”
BackgroundInfluentialSelf-citationReplacement Dosage of L-Thyroxine in Hypothyroidism: A Re-Evaluation
Stock, J. M., Surks, M. I., & Oppenheimer, J. H. (1974) · New England Journal of Medicine · doi:10.1056/nejm197403072901001 · Cited by 184 · cited 3×
“Whereas, prior to the institution of the TSH assay, typical maintenance doses of LT4 were in the 200–500 mcg/day range, doses were now typically closer to 100–150 mcg/day (3, 103, 105, 106).”
BackgroundIs a Normal TSH Synonymous With “Euthyroidism” in Levothyroxine Monotherapy?
Peterson, S. J., McAninch, E. A., & Bianco, A. C. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2660 · Cited by 182 · cited 3×
“Indeed, it has been shown in a large population study that LT4treated patients exhibit higher BMIs and take more statins and anti-depressants than TSH-matched, healthy controls (15); this association could have been impacted by confounding and thus further investigation is indicated to confirm these results (15).”
BackgroundSelf-citationEscobar-Morreale, H. F., Botella-Carretero, J. I., Gómez-Bueno, M., Galán, J. M., Barrios, V., & Sancho, J. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-142-6-200503150-00007 · Cited by 182 · cited 1×
“Indeed, many clinical trials show subjective “preference” for combination therapy without positive objective results when utilizing quality of life and/or thyroid-specific questionnaires (19, 21, 128, 129).”
BackgroundUtility of the Radioimmunoassay of Serum Thyrotrophin in Man
HERSHMAN, J. M., & PITTMAN, J. A. (1971) · Annals of Internal Medicine · doi:10.7326/0003-4819-74-4-481 · Cited by 159
Nygaard, B., Jensen, E. W., Kvetny, J., Jarløv, A., & Faber, J. (2009) · European Journal of Endocrinology · doi:10.1530/eje-09-0542 · Cited by 153
Hoang, T. D., Olsen, C. H., Mai, V. Q., Clyde, P. W., & Shakir, M. K. M. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-4107 · Cited by 151
DIO2 Thr92Ala Reduces Deiodinase-2 Activity and Serum-T3 Levels in Thyroid-Deficient Patients
Castagna, M. G., Dentice, M., Cantara, S., Ambrosio, R., Maino, F., Porcelli, T., Marzocchi, C., Garbi, C., Pacini, F., & Salvatore, D. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2587 · Cited by 151
Defending plasma T3 is a biological priority
Abdalla, S. M., & Bianco, A. C. (2014) · Clinical Endocrinology · doi:10.1111/cen.12538 · Cited by 147 · cited 3×
“The study of a number of animal models indicate that maintaining normal serum T3 levels is a biological priority (18).”
BackgroundIto, M., Miyauchi, A., Morita, S., Kudo, T., Nishihara, E., Kihara, M., Takamura, Y., Ito, Y., Kobayashi, K., Miya, A., et al. (2012) · European Journal of Endocrinology · doi:10.1530/eje-11-1029 · Cited by 133
Triiodothyronine Radioimmunoassay
Lieblich, J., & Utiger, R. D. (1972) · Journal of Clinical Investigation · doi:10.1172/jci106786 · Cited by 128 · cited 1×
“Soon thereafter was the development of RIAs for measurement of serum T3 (107, 108) and T4 (109).”
BackgroundThe history and future of treatment of hypothyroidism
McAninch, E. A., & Bianco, A. C. (2016) · Annals of Internal Medicine · doi:10.7326/m15-1799 · Cited by 118
Self-citationType 2 deiodinase polymorphism causes ER stress and hypothyroidism in the brain
Jo, S., Fonseca, T. L., Bocco, B. M. L. C., Fernandes, G. W., McAninch, E. A., Bolin, A. P., Da Conceição, R. R., Werneck-de-Castro, J. P., Ignacio, D. L., Egri, P., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci123176 · Cited by 107
Self-citationSmith, R. N., Taylor, S. A., & Massey, J. C. (1970) · BMJ · doi:10.1136/bmj.4.5728.145 · Cited by 106 · cited 1×
“For example, in studies utilizing doses of LT3 75–100 mcg/day, angina and congestive heart failure were observed (82); in another trial, palpitations, irritability, nervousness, dizziness, tremor, and perspiration were observed on LT4 (80 mcg) plus LT3 (20 mcg) daily (83).”
BackgroundReference intervals in the diagnosis of thyroid dysfunction: treating patients not numbers
Jonklaas, J., & Razvi, S. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30371-1 · Cited by 100
Wouters, H. J. C. M., van Loon, H. C. M., van der Klauw, M. M., Elderson, M. F., Slagter, S. N., Kobold, A. M., Kema, I. P., Links, T. P., van Vliet-Ostaptchouk, J. V., & Wolffenbuttel, B. H. R. (2017) · Thyroid® · doi:10.1089/thy.2016.0199 · Cited by 97
Cotton, G. E., Gorman, C. A., & Mayberry, W. E. (1971) · New England Journal of Medicine · doi:10.1056/nejm197109022851001 · Cited by 95 · cited 4×
“Whereas, prior to the institution of the TSH assay, typical maintenance doses of LT4 were in the 200–500 mcg/day range, doses were now typically closer to 100–150 mcg/day (3, 103, 105, 106).”
BackgroundInfluentialMcAninch, E. A., Rajan, K. B., Miller, C. H., & Bianco, A. C. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-01361 · Cited by 94
Self-citationCarlé, A., Faber, J., Steffensen, R., Laurberg, P., & Nygaard, B. (2017) · European Thyroid Journal · doi:10.1159/000469709 · Cited by 93
Torlontano, M., Durante, C., Torrente, I., Crocetti, U., Augello, G., Ronga, G., Montesano, T., Travascio, L., Verrienti, A., Bruno, R., et al. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-1067 · Cited by 92
Samuels, M. H., Kolobova, I., Smeraglio, A., Peters, D., Purnell, J. Q., & Schuff, K. G. (2016) · Thyroid · doi:10.1089/thy.2015.0345 · Cited by 87
Liothyronine use in a 17 year observational population‐based study ‐ the tears study
Leese, G. P., Soto‐Pedre, E., & Donnelly, L. A. (2016) · Clinical Endocrinology · doi:10.1111/cen.13052 · Cited by 75 · cited 1×
“There are theoretical concerns about adverse events with LT3 treatment, but in one observational study over 17 years, there were no increased cardiovascular or skeletal risks (130).”
BackgroundChalmers, J. R., Dickson, G. T., Elks, J., & Hems, B. A. (1949) · Journal of the Chemical Society (Resumed) · doi:10.1039/jr9490003424 · Cited by 67
Levothyroxine therapy and serum free thyroxine and free triiodothyronine concentrations
Woeber, K. A. (2002) · Journal of Endocrinological Investigation · doi:10.1007/bf03343972 · Cited by 67
Medici, B. B., Nygaard, B., la Cour, J. L., Grand, M. K., Siersma, V., Nicolaisdottir, D. R., Lind, B., Olivarius, N. D. F., & Andersen, C. L. (2019) · Thyroid® · doi:10.1089/thy.2018.0539 · Cited by 63
A Common DIO2 Polymorphism and Alzheimer Disease Dementia in African and European Americans
McAninch, E. A., Rajan, K. B., Evans, D. A., Jo, S., Chaker, L., Peeters, R. P., Bennett, D. A., Mash, D. C., & Bianco, A. C. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-01196 · Cited by 59
Self-citationNew insights into the variable effectiveness of levothyroxine monotherapy for hypothyroidism
McAninch, E. A., & Bianco, A. C. (2015) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00325-3 · Cited by 39
Self-citationTSH may not be a good marker for adequate thyroid hormone replacement therapy
Alevizaki, M., Mantzou, E., Cimponeriu, A. T., Alevizaki, C. C., & Koutras, D. A. (2005) · Wiener klinische Wochenschrift · doi:10.1007/s00508-005-0421-0 · Cited by 34
MANGIERI, C. N., & LUND, M. H. (1970) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-30-1-102 · Cited by 27
Medici, B. B., la Cour, J. L., Michaelsson, L. F., Faber, J. O., & Nygaard, B. (2017) · European Thyroid Journal · doi:10.1159/000454878 · Cited by 25 · cited 1×
“In a study of 42 patients, assessment of serum T3 at baseline and during combination therapy did not predict positive, symptomatic response (127).”
BackgroundJonklaas, J., Tefera, E., & Shara, N. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00031 · Cited by 23
Da Conceição, R. R., Fernandes, G. W., Fonseca, T. L., Bocco, B. M. L. C., & Bianco, A. C. (2018) · Thyroid · doi:10.1089/thy.2018.0205 · Cited by 23
Self-citationPhysiologic combinations of synthetic thyroid hormones in myxedema
Wool, M. S., & Selenkow, H. A. (1965) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt196566710 · Cited by 17
Taylor, S. (1961) · The Lancet · doi:10.1016/s0140-6736(61)91516-1 · Cited by 9
Cited by
Mitchell, A. L., Hegedüs, L., Žarković, M., Hickey, J. L., & Perros, P. (2021) · Clinical Endocrinology · doi:10.1111/cen.14340 · Cited by 81
Individualized Therapy for Hypothyroidism: Is T4 Enough for Everyone?
Ettleson, M. D., & Bianco, A. C. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa430 · Cited by 75
Self-citationMillan-Alanis, J. M., González-González, J. G., Flores-Rodríguez, A., Singh Ospina, N., Maraka, S., Moreno-Peña, P. J., Brito, J. P., González-Velázquez, C., & Rodríguez-Gutiérrez, R. (2021) · Thyroid® · doi:10.1089/thy.2021.0270 · Cited by 60
Patient Experiences and Perceptions Associated with the Use of Desiccated Thyroid Extract
Toloza, F. J. K., Espinoza Suarez, N. R., El Kawkgi, O., Golembiewski, E. H., Ponce, O. J., Yao, L., Maraka, S., Singh Ospina, N. M., & Brito, J. P. (2020) · Medicina · doi:10.3390/medicina56040161 · Cited by 22
Riis, K. R., Larsen, C. B., & Bonnema, S. J. (2024) · Thyroid® · doi:10.1089/thy.2023.0649 · Cited by 10
“D esiccated thyroid extract (DTE), derived from the porcine or bovine thyroid gland, was the standard therapy for hypothyroidism until the mid-1970s, 1 but is no longer recommended by guidelines worldwide.”
Metadata
- Authors
- McAninch, E. A., & Bianco, A. C.
- Venue
- Frontiers in Endocrinology
- Publisher
- Frontiers Media SA
- Published
- 2019-07-09
- Volume
- 10
- Pages
- 446-446
- ISSN
- 1664-2392 (ISSN-L)
- OpenAlex
- W2958491556
- Cited by
- 24
- References
- 56
- FWCI
- 2.06
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.